knowledge -WSS

knowledge

author：fashion 2025-10-01 00:52:49 - browse：38

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Congress may force more Covid

hotspot

WSS

Abridge raises $150m as clinical notes automation market heats up

Obamacare plans could cover weight loss drugs

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Reporting on presidential health from Reagan to Trump and Biden

Researchers tackle phage therapy hurdles for wider adoption

hotspot

knowledge

knowledge

Activists slam private health insurers over coverage restrictions

Scientific mystery highlights the blind spots in genomics databases

How to save PrEP access — and even expand it

Alzheimer's risk factor APOE4 may be a distinct form of the disease

How one medical school became remarkably diverse

Pancreatic cancer is often deadly, but new discoveries are raising hope

After affirmative action ruling, medical educators look to 'holistic review'

Flagship Pioneering startup Sonata Therapeutics lays off 21

Jerome Adams on the need for new antivirals for Covid

Medicare Advantage enrollment hits roughly 33.4 million

Wikipedia

Pancreatic cancer is often deadly, but new discoveries are raising hope

Drug companies' payments and gifts affect physicians' prescribing

U.K. decision on ALS drug has neurologists, advocates up in arms

Reporting on presidential health from Reagan to Trump and Biden

New CMS data security rules will hurt Medicare, Medicaid research

Alzheimer's risk factor APOE4 may be a distinct form of the disease

hotspot

hotspot

focus

knowledge